Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fair Resource Allocation

Health technology assessment plays a pivotal role in resource-constrained healthcare systems. How can organizations like NICE, ICER, and Canada’s Drug Agency better incorporate novel value elements into economic evaluations? They can do so by adopting a principled framework that evolves beyond traditional Quality-Adjusted Life Years (QALYs). This approach ensures fair resource allocation. A report from the Health Economics Methods Advisory (HEMA) group, convened by these leaders, guides this shift. It draws on ideas like the ISPOR Value Flower to emphasize relevance, valuation, and opportunity costs. These steps maintain evidence-based priorities in health technology assessment.

Health technology assessment must evolve economic evaluation methods carefully. A new HEMA report outlines this path. It includes novel value elements beyond core QALYs. The report uses three principles: relevance to decision-makers, aggregation with public preferences, and symmetric opportunity costs. It appraises ideas like risk attitudes, equity weights, and productivity impacts. The goal is cautious adoption with strong evidence. This avoids misallocation in tax- or insurance-funded systems.

HEMA’s Clear Guidance

The HEMA report simplifies health economics debates into clear guidance. It highlights trends like generalized cost-effectiveness analysis (GCEA), yet it warns against unproven changes. Key points include:

• Principles for Benefit Inclusion: Additions must fit HTA’s focus on population health. They should not prioritize individual utility. For example, “value of hope” from risk-seeking in severe illness needs public valuations. This ensures consistency across diseases, unlike patient-specific views.
• In-Scope Novel Elements: Four areas stand out: individual risk attitudes (like prudence for positive outcome skews), process utility (value of diagnostic info beyond health gains), equity adjustments (weighting for disadvantaged groups via distributional cost-effectiveness analysis or DCEA), and broader views (productivity spillovers or family effects). These link to concepts like severity modifiers and spillover benefits. They enrich core QALY metrics.
• Challenges and Trends: Frameworks like the ISPOR Value Flower often ignore opportunity costs—the health lost by funding new tech elsewhere. This risks bias. Evidence shows low adoption of alternatives like equal value life-years (evLY) or health years in total (HYT). They mismatch public preferences. Hybrid methods emerge, using qualitative input for unquantifiable elements like scientific spillovers. This balances rigor with nuance in HTA processes.

Reshaping Global Health Economics

Redefining benefits in health technology assessment reshapes global health economics. How does this affect outcomes research? The HEMA framework promotes equitable allocation but it requires rigor to avoid biases. In health economics, tools like DCEA highlight inequalities. This could boost funding for socioeconomic-targeted interventions. Without symmetric weighting, opportunity costs might widen gaps.

Outcomes research gains from hybrid models. These blend QALYs with process utilities, like value of knowing in diagnostics. They improve patient metrics like HRQoL, while clusters around risk protection and spillover effects add depth. Productivity inclusion may raise thresholds. HTA agencies must pilot changes before broader implementation. This ensures transparent trade-offs, like health versus societal benefits.

Overall, this fosters holistic research. It supports sustainable innovations if opportunity costs are reflected.

FAQ

How do novel value elements like equity weights impact health technology assessment decisions?
Equity weights in DCEA prioritize gains for disadvantaged groups. They may favor costlier interventions for severe or unequal conditions. Consistent use prevents double-counting, and it balances opportunity costs across evaluations.

What is the role of opportunity costs in redefining benefits for health economic evaluation?
Opportunity costs mean health forgone by funding new technologies. The report requires symmetric accounting for any extension, like productivity. This ensures fair allocation in systems like the NHS or U.S. insurance.

Can patient-specific risk attitudes replace public preferences in health technology assessment benefits?
No. HTA targets population decisions with average public views for consistency. Patient attitudes suit clinical choices. More research could use public risk data for future modifiers.

Conclusion

This report advances health technology assessment by balancing innovation with evidence. Key takeaways: Prioritize relevance, public values, and costs for equitable HTA.